Cost of diabetes medications
Pro Research Analysisby 
Searched over 200M research papers
Rising Costs of Diabetes Medications in the United States
The cost of diabetes medications in the United States has increased dramatically over the past two decades. National spending on glucose-lowering drugs rose from $16.9 billion to $57.6 billion per year between 2005–2007 and 2015–2017, a 240% increase. During this period, the average annual cost per user jumped from $1,106 to $2,727, representing a 147% rise, while the number of people using these drugs increased by 38% . From 2014 to 2019, the average monthly cost per user for antidiabetic medications increased by 47.5%, with newer drug classes like SGLT2 inhibitors and GLP-1 receptor agonists contributing significantly to these rising costs .
Factors Driving High Diabetes Medication Prices
Several factors contribute to the high and rising costs of diabetes medications in the U.S. Pharmaceutical manufacturers set the prices for new products, and there has been a shift from older, less expensive insulins to newer, genetically engineered human insulins and insulin analogs, which are much more costly. Additionally, nontransparent negotiations of rebates and discounts, limited ability for payers to negotiate prices, and physician prescribing practices have all played a role in driving up expenditures . Insulin, in particular, has seen a sixfold increase in expenditures between 2002 and 2012 .
Out-of-Pocket Costs and Financial Burden
Out-of-pocket costs for people with diabetes are substantial, especially for those with type 1 diabetes (T1D). In 2018, average out-of-pocket costs were $2,037 for T1D and $1,543 for type 2 diabetes (T2D), with medication costs making up the largest share (over 50%) of these expenses . When people with T2D transition to Medicare at age 65, their quarterly out-of-pocket costs for diabetes drugs increase by an average of $23, with even higher increases for those with greater medication needs. This often leads to reduced medication adherence and worse health outcomes .
Price Variation by Pharmacy and Drug Type
The cash price of diabetes medications varies widely depending on the type of drug and the pharmacy. Brand-name therapies have the highest average price per unit ($149), followed by insulins ($42), and generic therapies ($1.30). Chain pharmacies generally offer lower and more consistent prices compared to independent pharmacies, and the greatest price variation is seen in non-insulin generic therapies .
International and Low-Resource Settings
In low- and middle-income countries, annual medication costs for diabetes range from $15 to over $500, with insulin showing particularly wide variation. The median annual medication cost is about $177, but costs can be much higher for those requiring insulin or with complications . In Africa, drug costs are a significant portion of total diabetes treatment expenses, and the financial burden is especially high for low-income individuals .
Potential for Lower-Cost Alternatives
Economic evaluations suggest that diabetes medications could be manufactured and sold at prices far below current market rates. For example, SGLT2 inhibitors could be produced for $1.30 to $3.45 per month, and mixed human insulin could cost as little as $61 per year. These findings indicate that there is significant potential to reduce prices and improve access if pricing were more closely aligned with production costs .
Policy Implications and the Need for Reform
The high cost of diabetes medications has become a barrier to effective treatment, particularly for the most vulnerable populations. Policy interventions such as increased price transparency, more opportunities for price negotiation, and outcomes-based pricing models are needed to control costs and improve access 13. Providers are encouraged to screen patients for financial hardship and advocate for policies that lower out-of-pocket costs, especially for essential medications .
Conclusion
The cost of diabetes medications continues to rise, placing a heavy financial burden on patients, especially those with type 1 diabetes and those without comprehensive insurance. While manufacturing costs are much lower than current market prices, systemic factors keep prices high. Addressing these challenges will require coordinated policy action, increased transparency, and a focus on making life-saving medications more affordable and accessible for all.
Sources and full results
Most relevant research papers on this topic